Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alternative RNA Splicing02:18

Alternative RNA Splicing

25.2K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
25.2K
Alternative RNA Splicing02:18

Alternative RNA Splicing

5.2K
5.2K
RNA Splicing01:32

RNA Splicing

60.6K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

929
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
929
Null and Alternative Hypotheses01:16

Null and Alternative Hypotheses

12.8K
The actual hypothesis testing begins by considering two hypotheses. They are termed  the null hypothesis and the alternative hypothesis. These hypotheses contain opposing viewpoints.
The null hypothesis, denoted by H0 is a statement of no difference between the variables—they are not related. This can often be considered the status quo. As  a result if you cannot accept the null, it requires some action.
The alternative hypothesis, denoted by H1 or Ha, is a claim about the...
12.8K
Chromatin Structure and RNA Splicing02:41

Chromatin Structure and RNA Splicing

3.5K
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From bats to humans: uncovering <i>ISG15</i> as a new resistance factor in type 1 diabetes.

bioRxiv : the preprint server for biology·2026
Same author

Nuclear speckle dynamics are controlled by polyphosphate inhibition of CLK proteins.

Nucleic acids research·2026
Same author

Long-read sequencing identifies aberrant fragmentation patterns linked to elevated cell-free DNA levels in cancer.

Genome biology·2026
Same author

Beyond bystanders: How β cell stress shapes the autoimmune response in T1D.

Science translational medicine·2026
Same author

Differential immune- and apoptosis-related gene signatures in pancreatic alpha and beta cells contribute to their fate in type 1 diabetes.

Cell death and differentiation·2026
Same author

Diabetes research enters the biobank era: searching for the truth in a deep well.

The Journal of clinical investigation·2025
Same journal

The Upfront Effectiveness of a 6-Week Continuous Glucose Monitoring Intervention for Non-Insulin-Using Individuals With Type 2 Diabetes Is No Longer Detectable at 6-12 Months: An Observational Follow-Up of a Randomized Trial Cohort.

Diabetes, obesity & metabolism·2026
Same journal

Modelling the Clinical and Complication-Related Economic Burden of Therapeutic Inertia in People With Type 2 Diabetes in China.

Diabetes, obesity & metabolism·2026
Same journal

Hypoglycaemia Was Not Associated With Depression, Anxiety, Diabetes Distress or Fear of Hypoglycaemia Scores in People With Type 1 or Insulin-Treated Type 2 Diabetes in the Hypo-METRICS Study.

Diabetes, obesity & metabolism·2026
Same journal

Pubertal Stage-Based One-hour Postload Glucose Thresholds Improve Identification of Prediabetes and Type 2 Diabetes in Children With Overweight or Obesity.

Diabetes, obesity & metabolism·2026
Same journal

GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.

Diabetes, obesity & metabolism·2026
Same journal

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study.

Diabetes, obesity & metabolism·2026
See all related articles

Related Experiment Video

Updated: Feb 5, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.4K

When one becomes many-Alternative splicing in β-cell function and failure.

Maria Inês Alvelos1, Jonàs Juan-Mateu1, Maikel Luis Colli1

  • 1ULB Center for Diabetes Research and Welbio, Medical Faculty, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Diabetes, Obesity & Metabolism
|September 20, 2018
PubMed
Summary
This summary is machine-generated.

Alternative splicing, a process regulating gene expression, is crucial for pancreatic beta-cell survival in type 1 diabetes (T1D). Understanding splicing regulators could lead to new T1D treatments.

Keywords:
alternative splicingcandidate genespancreatic β-cellssplicing factorstype 1 diabetes

More Related Videos

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

13.4K
Identification of Alternative Splicing and Polyadenylation in RNA-seq Data
08:35

Identification of Alternative Splicing and Polyadenylation in RNA-seq Data

Published on: June 24, 2021

6.5K

Related Experiment Videos

Last Updated: Feb 5, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.4K
Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

13.4K
Identification of Alternative Splicing and Polyadenylation in RNA-seq Data
08:35

Identification of Alternative Splicing and Polyadenylation in RNA-seq Data

Published on: June 24, 2021

6.5K

Area of Science:

  • Molecular Biology
  • Endocrinology
  • Genetics

Background:

  • Pancreatic beta-cell dysfunction and death are key in type 1 diabetes (T1D), but underlying molecular mechanisms are unclear.
  • Alternative splicing generates diverse mRNA and protein isoforms, increasing transcriptome complexity and protein variety.
  • RNA binding proteins (RBPs) and alternative exon networks are implicated in beta-cell function and survival, influenced by inflammation and diabetes genes.

Purpose of the Study:

  • To investigate the role of alternative splicing regulators and splice variants in pancreatic beta-cell function, dysfunction, and death.
  • To explore the potential for modulating alternative splicing as a therapeutic strategy for T1D.

Main Methods:

  • The study focuses on understanding the molecular mechanisms of alternative splicing in pancreatic beta-cells.
  • It examines the influence of specific RNA binding proteins (RBPs) and alternative exon networks.
  • The research considers the impact of inflammation and diabetes susceptibility genes on these processes.

Main Results:

  • Alternative splicing regulators and splice variants significantly impact beta-cell function and survival.
  • Specific RBPs enriched in beta-cells play critical roles in insulin secretion and cell viability.
  • Inflammation and diabetes-related genes modulate alternative exon networks essential for beta-cell health.

Conclusions:

  • Alternative splicing is a critical determinant of pancreatic beta-cell fate in T1D.
  • Targeting splicing regulators and variants presents a promising avenue for developing novel T1D therapies.
  • Further research is needed to fully elucidate and exploit the therapeutic potential of modulating alternative splicing in T1D.